ciltacabtagene autoleucel

{
  "id": "MLC-T-ONC-001768",
  "term": "ciltacabtagene autoleucel",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A treatment used for adults with multiple myeloma that came back or did not get better after treatment with at least one line of anticancer therapy that included a proteasome inhibitor and an immunomodulating agent. It is used in patients whose cancer did not respond to treatment with lenalidomide. Ciltacabtagene autoleucel is made using a patient’s T cells (a type of immune system cell). A gene for a special receptor called chimeric antigen receptor (CAR) is added to the T cells in the laboratory. These changed T cells called CAR T cells are grown in large numbers in the laboratory and given to the patient by infusion. Ciltacabtagene autoleucel binds to a protein called BCMA, which is found on myeloma cells and some types of immune cells. This helps the body’s immune system kill cancer cells. Ciltacabtagene autoleucel is a type of cellular immunotherapy called CAR T-cell therapy. Also called Carvykti.",
    "A preparation of autologous T lymphocytes that are transduced, ex vivo, with LCAR-B38M, a lentiviral vector expressing a chimeric antigen receptor (CAR) containing two bispecific anti-B-cell maturation antigen (BCMA) variable fragments of llama heavy-chain murine antibodies fused to the signaling domain of 4-1BB (CD137), with potential immunostimulating and antineoplastic activities. The antigen-binding region of the CAR is a non-scFv structure targeting two distinct regions of BCMA. Upon intravenous administration back into the patient, ciltacabtagene autoleucel are directed to cells expressing BCMA, bind to two different epitopes on BCMA and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-associated antigen (TAA) and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is overexpressed on malignant plasma cells."
  ],
  "synonyms": [
    "Carvykti",
    "LCAR-B38M-transduced CAR T Cells JNJ-68284528",
    "autologous anti-BCMA CAR T Cells JNJ-68284528",
    "autologous bi-epitope CAR T cells JNJ-68284528",
    "autologous bi-epitope BCMA-targeted CAR T cells JNJ-68284528",
    "cilta-cel"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ciltacabtagene-autoleucel/"
}